PHARMACOTHERAPEUTICS FOR
ADVANCED PRACTICE NURSE
PRESCRIBERS EXAM QUESTIONS AND
ANSWERS GRADED A+ 2025/2026
Estrogens - ANS Bind to estrogen receptors, influencing gene transcription and various
physiological processes.
Progestins - ANS Bind to progesterone receptors, regulating reproductive functions.
Hormone Replacement Therapy (HRT) - ANS Used in menopausal women for relief of
vasomotor symptoms, prevention of osteoporosis, and management of urogenital atrophy.
Combined Oral Contraceptives (COCs) - ANS Contain both estrogen and progestin, inhibit
ovulation, alter cervical mucus, and modify the endometrial lining to prevent pregnancy.
Androgens - ANS Bind to androgen receptors, promoting the development and maintenance
of male characteristics.
Male Hypogonadism - ANS Indication for androgen therapy.
Copper IUDs - ANS Non-hormonal intrauterine devices that create an inhospitable
environment for sperm.
1 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED.
,Levonorgestrel-releasing IUDs - ANS Hormonal intrauterine devices that may inhibit
implantation.
Polycystic Ovary Syndrome (PCOS) - ANS A reproductive disorder that can be managed with
pharmacologic interventions like COCs and Metformin.
Metformin - ANS Improves insulin sensitivity and may aid in ovulation for PCOS.
Anti-Androgens - ANS Medications like spironolactone used to address hirsutism and acne.
Endometriosis - ANS A reproductive disorder treated with NSAIDs, hormonal therapies, and
surgical interventions.
NSAIDs - ANS First-line treatment for pain management in endometriosis.
Selective Serotonin Reuptake Inhibitors (SSRIs) - ANS Non-hormonal alternatives for
managing menopausal symptoms.
Gabapentin - ANS Non-hormonal alternative for managing menopausal symptoms.
Thromboembolic Events - ANS Potential adverse effect of hormonal therapies.
Uterine Perforation - ANS A rare risk associated with IUDs.
Irregular Bleeding - ANS An adverse effect of progestin-only contraceptive methods.
Weight Gain - ANS An adverse effect associated with progestin-only contraceptive methods.
Mood Changes - ANS An adverse effect that can occur with hormonal therapies.
2 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED.
,Breast Cancer Risk - ANS Increased risk associated with combined hormone replacement
therapy.
Cardiovascular Events - ANS Potential risk associated with hormone replacement therapy.
Stroke - ANS A potential risk associated with hormone replacement therapy.
Counseling Points - ANS Discuss potential side effects and emphasize adherence to
prescribed regimens.
Monitoring - ANS Regular follow-ups to assess efficacy and tolerability of therapies.
Vasomotor Symptoms - ANS Symptoms like hot flashes that HRT aims to relieve.
Menstrual Disorders - ANS Conditions that can be managed with hormonal therapies.
Contraceptive Benefits - ANS Regulation of menstrual cycles and reduction in menstrual
cramps.
Contraindications for COCs - ANS History of thromboembolic disorders, uncontrolled
hypertension, and migraines with aura.
Progestin-Only Methods - ANS Include pills, injectables (e.g., Depo-Provera), and implants
(e.g., Nexplanon).
Monitoring - ANS Regular follow-ups to assess efficacy and tolerability.
Routine screenings - ANS Screenings as indicated (e.g., blood pressure checks, lipid profiles).
3 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED.
, Androgen Therapy - ANS Short-term use of androgens in male patients has been associated
with an increased risk of hepatocellular carcinoma.
Antihypertensive Agents - ANS Medications used to manage high blood pressure.
Angiotensin-Converting Enzyme (ACE) Inhibitors - ANS Inhibit the conversion of angiotensin I
to angiotensin II, leading to vasodilation and decreased aldosterone secretion.
Indications for ACE Inhibitors - ANS Hypertension, heart failure, diabetic nephropathy.
Adverse Effects of ACE Inhibitors - ANS Cough, hyperkalemia, angioedema.
Monitoring for ACE Inhibitors - ANS Renal function and serum potassium levels.
Angiotensin II Receptor Blockers (ARBs) - ANS Block angiotensin II receptors, preventing
vasoconstriction and aldosterone effects.
Indications for ARBs - ANS Similar to ACE inhibitors; used when ACE inhibitors are not
tolerated.
Adverse Effects of ARBs - ANS Hyperkalemia, renal impairment.
Monitoring for ARBs - ANS Renal function and serum potassium levels.
Calcium Channel Blockers - ANS Inhibit calcium influx into vascular smooth muscle and
myocardium, leading to vasodilation and decreased myocardial contractility.
Indications for Calcium Channel Blockers - ANS Hypertension, angina, certain arrhythmias.
4 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED.
ADVANCED PRACTICE NURSE
PRESCRIBERS EXAM QUESTIONS AND
ANSWERS GRADED A+ 2025/2026
Estrogens - ANS Bind to estrogen receptors, influencing gene transcription and various
physiological processes.
Progestins - ANS Bind to progesterone receptors, regulating reproductive functions.
Hormone Replacement Therapy (HRT) - ANS Used in menopausal women for relief of
vasomotor symptoms, prevention of osteoporosis, and management of urogenital atrophy.
Combined Oral Contraceptives (COCs) - ANS Contain both estrogen and progestin, inhibit
ovulation, alter cervical mucus, and modify the endometrial lining to prevent pregnancy.
Androgens - ANS Bind to androgen receptors, promoting the development and maintenance
of male characteristics.
Male Hypogonadism - ANS Indication for androgen therapy.
Copper IUDs - ANS Non-hormonal intrauterine devices that create an inhospitable
environment for sperm.
1 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED.
,Levonorgestrel-releasing IUDs - ANS Hormonal intrauterine devices that may inhibit
implantation.
Polycystic Ovary Syndrome (PCOS) - ANS A reproductive disorder that can be managed with
pharmacologic interventions like COCs and Metformin.
Metformin - ANS Improves insulin sensitivity and may aid in ovulation for PCOS.
Anti-Androgens - ANS Medications like spironolactone used to address hirsutism and acne.
Endometriosis - ANS A reproductive disorder treated with NSAIDs, hormonal therapies, and
surgical interventions.
NSAIDs - ANS First-line treatment for pain management in endometriosis.
Selective Serotonin Reuptake Inhibitors (SSRIs) - ANS Non-hormonal alternatives for
managing menopausal symptoms.
Gabapentin - ANS Non-hormonal alternative for managing menopausal symptoms.
Thromboembolic Events - ANS Potential adverse effect of hormonal therapies.
Uterine Perforation - ANS A rare risk associated with IUDs.
Irregular Bleeding - ANS An adverse effect of progestin-only contraceptive methods.
Weight Gain - ANS An adverse effect associated with progestin-only contraceptive methods.
Mood Changes - ANS An adverse effect that can occur with hormonal therapies.
2 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED.
,Breast Cancer Risk - ANS Increased risk associated with combined hormone replacement
therapy.
Cardiovascular Events - ANS Potential risk associated with hormone replacement therapy.
Stroke - ANS A potential risk associated with hormone replacement therapy.
Counseling Points - ANS Discuss potential side effects and emphasize adherence to
prescribed regimens.
Monitoring - ANS Regular follow-ups to assess efficacy and tolerability of therapies.
Vasomotor Symptoms - ANS Symptoms like hot flashes that HRT aims to relieve.
Menstrual Disorders - ANS Conditions that can be managed with hormonal therapies.
Contraceptive Benefits - ANS Regulation of menstrual cycles and reduction in menstrual
cramps.
Contraindications for COCs - ANS History of thromboembolic disorders, uncontrolled
hypertension, and migraines with aura.
Progestin-Only Methods - ANS Include pills, injectables (e.g., Depo-Provera), and implants
(e.g., Nexplanon).
Monitoring - ANS Regular follow-ups to assess efficacy and tolerability.
Routine screenings - ANS Screenings as indicated (e.g., blood pressure checks, lipid profiles).
3 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED.
, Androgen Therapy - ANS Short-term use of androgens in male patients has been associated
with an increased risk of hepatocellular carcinoma.
Antihypertensive Agents - ANS Medications used to manage high blood pressure.
Angiotensin-Converting Enzyme (ACE) Inhibitors - ANS Inhibit the conversion of angiotensin I
to angiotensin II, leading to vasodilation and decreased aldosterone secretion.
Indications for ACE Inhibitors - ANS Hypertension, heart failure, diabetic nephropathy.
Adverse Effects of ACE Inhibitors - ANS Cough, hyperkalemia, angioedema.
Monitoring for ACE Inhibitors - ANS Renal function and serum potassium levels.
Angiotensin II Receptor Blockers (ARBs) - ANS Block angiotensin II receptors, preventing
vasoconstriction and aldosterone effects.
Indications for ARBs - ANS Similar to ACE inhibitors; used when ACE inhibitors are not
tolerated.
Adverse Effects of ARBs - ANS Hyperkalemia, renal impairment.
Monitoring for ARBs - ANS Renal function and serum potassium levels.
Calcium Channel Blockers - ANS Inhibit calcium influx into vascular smooth muscle and
myocardium, leading to vasodilation and decreased myocardial contractility.
Indications for Calcium Channel Blockers - ANS Hypertension, angina, certain arrhythmias.
4 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED.
